Related Experiment Video
Updated: Jan 19, 2026
Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines
Published on: August 21, 2019
PARK2 Suppresses Proliferation and Tumorigenicity in Non-small Cell Lung Cancer
Huijie Duan1,2, Zhong Lei3, Fei Xu4
1Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Abstract:
Aims: PARK2 mutation is originally associated with the progression of Parkinson's disease. In recent years, PARK2 has been reported as a tumor suppressor gene in various cancers, including lung cancer. However, the biological functions and potential molecular mechanisms of PARK2 in non-small cell lung cancer (NSCLC) are still unclear. Methods: The level of PARK2 expression in 32 tissue samples of NSCLC and matched non-tumor lung tissues was detected by Western blot, and 64 specimens of NSCLC tissues were detected by immunohistochemistry. H1299 and H460 cell lines were used to PARK2 overexpression models, and H460 cell line was also used to PARK2 knockdown model. Using cell viability, colony formation, cell cycle, apoptosis, migration, and invasion assay, the biological functions of PARK2 were evaluated and the potential molecular mechanism of PARK2 was investigated in vitro. Meanwhile, 22 nude mice were employed for in vivo studies. Results: Western blot analysis revealed a decrease of PARK2 protein expression in human NSCLC samples. Immunohistochemistry also identified a vastly reduced expression of PARK2 in NSCLC (72%) and low PARK2 expression was significantly associated with tumor histological grade, lymph node metastasis and advanced TNM stage. Overexpression of PARK2 suppressed cell proliferation, colony formation, migration, and invasion, arrested cell cycle progression in the G1 phase, and induced apoptosis in human non-small cell lines H1299 and H460 in vitro. Meanwhile, knockdown of PARK2 had the opposite biological functions. In addition, PARK2 significantly decreased the tumor volumes in subcutaneous xenograft model and reduced the incidence of metastatic tumors in the transfer model. Exploration of the molecular mechanism of PARK2 in NSCLC showed that PARK2 negatively regulated the EGFR/AKT/mTOR signaling pathway. Conclusions: PARK2 was an important tumor suppressor in NSCLC, which might inhibit cancer growth and metastases through the down regulation of the EGFR/AKT/mTOR signaling pathway.
Insights
The PARK2 gene acts as a tumor suppressor in non-small cell lung cancer (NSCLC), inhibiting tumor growth and metastasis by downregulating the EGFR/AKT/mTOR pathway.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- The PARK2 gene, initially linked to Parkinson's disease, is increasingly recognized for its tumor suppressor roles in various cancers.
- The specific functions and molecular mechanisms of PARK2 in non-small cell lung cancer (NSCLC) remain largely undefined.
- Understanding PARK2's role is crucial for developing novel therapeutic strategies against NSCLC.
Purpose of the Study:
- To investigate the expression levels of PARK2 in NSCLC tissues and cell lines.
- To elucidate the biological functions of PARK2 in NSCLC progression, including proliferation, migration, and apoptosis.
- To explore the underlying molecular mechanisms by which PARK2 exerts its tumor-suppressive effects in NSCLC.
Main Methods:
- Western blot and immunohistochemistry were used to assess PARK2 protein expression in NSCLC and normal lung tissues.
- In vitro studies involved PARK2 overexpression and knockdown models in NSCLC cell lines (H1299, H460) to evaluate cell viability, colony formation, cell cycle, apoptosis, migration, and invasion.
- In vivo studies utilized subcutaneous xenograft and metastasis models in nude mice to assess tumor growth and metastatic potential.
Main Results:
- PARK2 protein expression was significantly decreased in NSCLC tissues and associated with advanced tumor grade, lymph node metastasis, and TNM stage.
- Overexpression of PARK2 suppressed NSCLC cell proliferation, colony formation, migration, and invasion, while inducing G1 cell cycle arrest and apoptosis.
- PARK2 inhibited tumor growth and reduced metastasis in vivo, acting through negative regulation of the EGFR/AKT/mTOR signaling pathway.
Conclusions:
- PARK2 functions as a critical tumor suppressor in non-small cell lung cancer.
- PARK2 inhibits NSCLC growth and metastasis by downregulating the EGFR/AKT/mTOR signaling pathway.
- Targeting PARK2 or its downstream pathways may offer a promising therapeutic avenue for NSCLC treatment.
More Related Videos
Related Concept Videos
09:45Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines
07:31Soft Agar Colony Formation Assay: A Method to Test Effects of Novel Compounds on Cancer Cell Proliferation
12:35Comparison of Three Different Methods for Determining Cell Proliferation in Breast Cancer Cell Lines
03:19Co-culturing BC Cells: Culturing Breast Cancer Cells with Bone Fragments to Study Cancer Cell Proliferation
05:17Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
11:06Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells